Yong-Chan Kim
Direktor/Vorstandsmitglied bei BAUDAX BIO, INC.
Vermögen: 32 $ am 31.05.2024
Profil
Yong-Chan Kim is the founder and current Chief Executive Officer & Director of TeraImmune, Inc., which is founded in 2016.
He is also currently an Independent Director at Baudax Bio, Inc. since 2023.
Dr. Kim holds a doctorate degree from Chungnam National University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
07.09.2023 | 4 520 ( 16,69% ) | 32 $ | 31.05.2024 |
Aktive Positionen von Yong-Chan Kim
Unternehmen | Position | Beginn |
---|---|---|
BAUDAX BIO, INC. | Direktor/Vorstandsmitglied | 03.07.2023 |
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Gründer | 01.01.2016 |
Ausbildung von Yong-Chan Kim
Chungnam National University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BAUDAX BIO, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |